June 24, 2026 — Alvotech (Nasdaq: ALVO) announced on June 8, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Takeda's Entyvio (vedolizumab) for intravenous administration. The BLA acceptance marks the first biosimilar filing for vedolizumab — a gut-selective integrin monoclonal antibody generating approximately $5.8 billion in annual global revenue — and signals a new wave of biosimilar competition in inflammatory bowel disease (IBD). Under the partnership, Alvotech handles development and manufacturing while Teva manages commercialization.
Entyvio (vedolizumab) occupies a unique position in inflammatory bowel disease treatment. As a gut-selective alpha-4-beta-7 integrin antagonist, vedolizumab specifically targets gut-homing lymphocytes — reducing intestinal inflammation without the systemic immunosuppression associated with broader anti-inflammatory agents. The drug is approved for moderately to severely active ulcerative colitis and Crohn's disease, two chronic conditions affecting an estimated 3.1 million patients in the United States.
Entyvio's favorable safety profile compared to TNF-alpha inhibitors and newer JAK inhibitors has driven sustained commercial growth. The drug's $5.8 billion in global annual revenue makes it one of the largest biologics facing patent expiry, creating one of the most significant biosimilar development opportunities in gastroenterology.
The Alvotech-Teva BLA is notable as a proposed interchangeable biosimilar. Under the Biologics Price Competition and Innovation Act (BPCIA), interchangeability allows pharmacy-level substitution without prescriber intervention — a critical regulatory distinction that directly affects market access and formulary positioning. The FDA's March 2026 biosimilar guidance eliminated the default three-way PK bridging study requirement, potentially reducing development costs by up to $20 million per program.
Vedolizumab presents specific manufacturing challenges that differentiate it from other monoclonal antibody biosimilars. Glycosylation Pattern Control: Vedolizumab's mechanism depends on specific glycosylation modifications at the Fc region. Biosimilar manufacturers must demonstrate comparability of glycan profiles using charge variant analysis, glycopeptide mapping, and lectin binding assays. Higher-Order Structure: The integrin-binding domain requires intact secondary and tertiary structure for gut-selective targeting, necessitating CD spectroscopy, differential scanning calorimetry, and HDX-MS for comparability. Immunogenicity: As a gut-selective biologic, vedolizumab's immunogenicity profile is influenced by interaction with gut-associated lymphoid tissue, requiring comprehensive anti-drug antibody testing.
The filing creates demand signals across multiple manufacturing segments:
Cell Culture and Upstream: CHO cell line development for high-titer vedolizumab expression, serum-free chemically defined media, and single-use bioreactor components.
Downstream Purification: Protein A affinity chromatography resins (MabSelect), ion exchange and mixed-mode media for glycosylation-selective polishing, and viral clearance filters.
Analytical Characterization: Intact mass analysis, peptide mapping, glycan profiling using HILIC-UPLC and CE-LIF, and forced degradation studies.
Fill-Finish: Lyophilized vial formulation, GMP-grade excipients (sucrose, polysorbate 80, histidine buffer), and pre-filled syringe components for emerging subcutaneous formulations.
Several factors accelerate the IBD biosimilar pipeline. At $5.8 billion in annual sales, vedolizumab represents one of the largest biologics approaching patent expiry. Regulatory streamlining — including elimination of three-way PK bridging studies — reduces costs and timelines. The interchangeability pathway enables pharmacy-level substitution, significantly expanding commercial opportunity. With IBD treatments exceeding $70,000 per patient annually, biosimilar competition could dramatically improve patient access while reducing healthcare costs.
Alvotech-Teva face competition from Celltrion (leveraging established biologics infrastructure), Samsung Bioepis (expanding through its Sandoz alliance), Amgen's biosimilar division, and Chinese manufacturers including Biocon and Innovent Biologics. The first-to-file advantage — potentially 12 months of market exclusivity — underscores the strategic importance of filing timing in the biosimilar market.
Invest in glycosylation analytical capabilities: Vedolizumab's mechanism depends on precise glycan structures, making glycosylation characterization a critical differentiator
Build integrin biology expertise: Gut-selective biologics require specialized knowledge of mucosal immunology
Prepare for rapid scale-up: The IBD biosimilar market requires rapid transition from clinical to commercial manufacturing
Engage with multiple developers: The competitive landscape supports multiple suppliers, diversifying revenue risk
Alvotech and Teva's FDA acceptance for AVT16 is more than a single regulatory milestone — it illuminates the path toward affordable IBD treatment. For biologics API manufacturers, CDMO service providers, and analytical specialists, the IBD biosimilar era is approaching. Companies that invest now in glycosylation expertise, integrin biology knowledge, and regulatory readiness will be best positioned to capture value from one of the most significant biosimilar entry opportunities in gastroenterology.
